Jb Chemicals & Pharmaceuticals Limited (JBCHEPHARM)

Loading page…

Jb Chemicals & Pharmaceuticals Limited (JBCHEPHARM) · mywealthgrid

About

JB Chemicals & Pharmaceuticals Limited is a pharmaceutical company within India's healthcare sector. With market capitalisation of ₹38,686.93 Cr, it operates as a mid-to-large cap player in the Indian pharma market. The company generates quarterly standalone revenue of ₹800–₹1,100 Cr with operating margins averaging 26.7%, indicating a sustainable profitable business model.

Face value: ₹1

Market cap

₹38,741 Cr

P/E

54.3×

P/B

9.3×

Dividend yield

1.2%

ROE

18.7%

ROCE

24.6%

Debt / equity

OPM

26.7%

EPS (TTM)

₹44.4

Book value

₹259.0

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

High valuation: PE of 54.2 relative to ROE of 18.69% leaves limited margin for disappointment
Recent revenue decline: Quarterly revenue fell from ₹1,065 Cr (Dec 2025) to ₹836–904 Cr (Mar 2026); verify root cause and sustainability
Margin compression: OPM fell from 28–29% (Sep–Dec 2025) to 22–23% (Mar 2026); verify if temporary or structural
Regulatory and pricing risk: Verify company's exposure to India's price-controlled pharmaceutical segments and policy sensitivity

Generated analysis · source review pending

Growth drivers

Revenue recovery to ₹1,000+ Cr (achieved in recent quarters) would expand absolute profitability given historical capacity
Operating margins of 28–29% (Sep–Dec 2025) show profitability structure; recovery to those levels concurrent with revenue growth would drive earnings expansion
Regular dividends over 20+ months demonstrate cash generation; retained earnings can fund expansion or strategic investments
Market pricing in growth: PE of 54.2 on ROE of 18.69% and 1y return of 47.55% indicate investor confidence in future performance

Generated analysis · source review pending

2,477 historical price candles were omitted because the exchange source has not been verified.

Only one verified price point is available. The trend chart will appear when more exchange closes are stored.

Quick read

rule-based

Pros

+High return on capital employed of 25.7%
+Healthy operating margin of 26.7%
+Revenue CAGR of 15.2% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 176.9×
+Dividend payout of 65.3% of profit

Cons

−Low return on equity of 6.1% (3-yr avg)
−Trading at 9.3× book value

Research score

Structured signal from quality, growth, valuation and momentum.

39/100

Business quality: 78
Growth

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,775	2,043	2,424	3,149	3,484	3,918	4,148
COGS	631	702	843	1,168	1,182	1,317	1,296
Gross profit	1,144	1,341	1,581	1,981	2,302	2,601	2,852
	766	781	1,038	1,285	1,405	1,570	1,744
	378	560	543	696	897	1,032	1,107
OPM %	21.3%	27.4%	22.4%	22.1%	25.7%	26.3%	26.7%
Depreciation	66	69	73	114	138	171	183
Interest	3	7	5	36	44	12	6
	41	112	39	10	37	38	33
Profit before tax	349	597	505	555	752	887	952
Tax	77	148	119	145	199	228	243
Tax %	21.9%	24.9%	23.5%	26.2%	26.5%	25.7%	25.5%
	272	449	386	410	553	660	709
PAT margin %	15.4%	22%	15.9%	13%	15.9%	16.8%	17.1%
EPS (₹)	34.2	58	49.9	53	35.7	42.5	45.2
EPS adjusted (₹)	17.6	29	24.9	26.5	-0.9	0.6	44.2
	32.2%	28.5%	33.1%	33.5%	34.4%	36.5%	48.7%
Annual report	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	17	17	17	16	15	15	15	15	16	16	16
Reserves	978	1,347	1,425	1,464	1,420	1,794	2,119	2,465	2,908	3,418	4,143
Minority interest	—	2	3	3	3	4	4	—	—	—	—
	193	49	29	26	29	33	26	548	357	14	0
	369	259	291	283	353	392	442	525	714	827	809
Total equity & liabilities	1,557	1,674	1,765	1,792	1,821	2,238	2,607	3,554	3,994	4,274	4,969
	440	679	640	621	651	634	1,277	1,901	2,004	1,968	1,885
CWIP	131	4	17	15	16	26	14	44	63	47	61
Investments	380	411	434	457	403	678	13	206	388	345	765
	607	580	674	699	750	901	1,304	1,402	1,538	1,914	2,257
Total assets	1,557	1,674	1,765	1,792	1,821	2,238	2,607	3,554	3,994	4,274	4,969

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	64.5%	65.7%	65.2%	62.9%	66.1%	66.4%	68.7%
EBITDA margin %	21.3%	27.4%	22.4%	22.1%	25.7%	26.3%	26.7%
EBIT margin %	17.5%	24.1%	19.4%	18.5%	21.8%	22%	22.3%
PAT margin %	15.4%	22%	15.9%	13%	15.9%	16.8%	17.1%
Working capital
Receivable days	71	70	84	67	72	76	69
Inventory days	159	181	178	135	155	147	192
Payable days	97	97	97	75	110	114	110
NWC days	133	153	164	127	117	109	151
Leverage
Current ratio	3.43	4.5	3.32	2.8	2.15	3.06	4.98
Debt to EBITDA	0.08	0.06	0.05	0.79	0.4	0.01	0
Debt to equity	0.02	0.02	0.01	0.22	0.12	0	0
Interest coverage	119.4	83.4	99.6	16.4	18	76.7	176.9
Asset turnover	0.97	0.91	0.93	0.89	0.87	0.92	0.83
Return ratios
Return on assets %	15%	20%	14.8%	11.5%	13.8%	15.4%	14.3%
Return on capital employed %	24%	35.5%	24.8%	22.6%	26%	26.6%	24.6%
Return on equity %	19%	24.8%	18.1%	16.5%	18.9%	19.2%	17.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	53.91%	53.86%	53.83%	53.78%	53.77%	53.74%	53.66%	47.84%	47.73%	47.56%	47.55%	48.8%
	9.54%	10.05%	10.35%	11.06%	12.17%	13.63%	14.64%	18.3%	17.77%	15.3%	14.88%	16.33%
	18.65%	18.58%	18.54%	18.38%	17.62%	16.81%	16.41%	18.72%	19.63%	22.83%	23.36%	21.38%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	17.9%	17.51%	17.28%	16.78%	16.44%	15.82%	15.29%	15.14%	14.87%	14.31%	14.21%	13.49%
No. of shareholders	—	—	—	—	—	—	—	—	—	71,957	69,338	74,043

Promoter holding down 5.11 percentage points since Jun 2023.

12 disclosures

Person	Deal	Shares	Value	Holding	Filed
Narayan Prasad SarafKey Managerial Personnel	Pledge RevokeRevokation of Pledge	1,148	₹19.67 L	0.00% → 0.00%	4 Oct 20257(2)
Pradeep Kumar SinghEmployees/Designated Employees	Pledge RevokeRevokation of Pledge	560	₹9.69 L

7 deals · 25 Jan 2024 – 27 Mar 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
27 Mar 2025	TAU INVESTMENT HOLDINGS PTE LIMITED	Bulk	NSE	Sell	22,45,787	₹1,625.00	₹364.94 Cr
27 Mar 2025	TAU INVESTMENT HOLDINGS PTE LIMITED	Bulk	NSE	Sell	22,45,786	₹1,625.34	₹365.02 Cr
27 Mar 2025	TAU INVESTMENT HOLDINGS PTE LIMITED	Bulk	NSE	Sell	22,45,786	₹1,625.01	₹364.94 Cr
27 Mar 2025	TAU INVESTMENT HOLDINGS PTE LIMITED	Bulk	NSE	Sell	22,45,786	₹1,625.00	₹364.94 Cr
27 Mar 2025	KOTAK MAHINDRA MUTUAL FUND	Bulk	NSE	Buy	12,30,769	₹1,625.00	₹200.00 Cr
25 Jan 2024	SOCIETE GENERALE	Block	BSE	Buy	1,04,241	₹1,693.80	₹17.66 Cr
25 Jan 2024	BNP PARIBAS ARBITRAGE	Block	BSE	Sell	1,04,241	₹1,693.80	₹17.66 Cr

1–7 of 7

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Arun DuggalNon-Executive - Independent Director-Chairperson
Mr. Sumit BoseNon-Executive - Independent Director
Mr. Ashwani Kumar PuriNon-Executive - Independent Director
Ms. Richa AroraNon-Executive - Independent Director
Mr. Aman MehtaExecutive Director-MD
Mr. Sudhir MenonNon-Executive - Non Independent Director
Mr. Amal Satyawan KelshikarNon-Executive - Non Independent Director
Mr. Hasmukh Mathurbhai PatelNon-Executive - Non Independent Director
Mr. Kaushal SolankiChief Financial Officer
Mr. Sandeep PhadnisCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 18 fund houses

Held by these funds

7.92%

of the company's equity

All mutual funds

19%

shareholding pattern, Mar 2026

Portfolios as of

June 2026

compared with May 2026

79 schemes · 18 fund houses

		Shares
Portfolio of Kotak Midcap FundNEW	Kotak Mahindra Mutual Fund	48.17 L	1,105.91	1.64%	2.999%	—
SMALL CAP FUNDNEW	Nippon India Mutual Fund	9.91 L	227.55	0.29%	0.617%	—
Franklin India Large Cap Fund (Formerly known as Franklin India Bluechip Fund)^NEW	Franklin Templeton Mutual Fund	7.78 L	178.59	2.46%	0.484%	—
Portfolio of Kotak Small Cap FundNEW	Kotak Mahindra Mutual Fund	7.15 L	164.11	0.88%	0.445%	—
Flexi Cap FundNEW	Nippon India Mutual Fund	5.28 L	121.33	1.27%	0.329%	—
Franklin India Large & Mid Cap Fund (Formerly known as Franklin India Equity Advantage Fund)^NEW	Franklin Templeton Mutual Fund	4.05 L	92.94	2.69%	0.252%	—
Portfolio of Kotak MNC FundNEW	Kotak Mahindra Mutual Fund	3.55 L	81.5	3.74%	0.221%	—
Portfolio of Kotak Balanced Advantage FundNEW	Kotak Mahindra Mutual Fund	3.52 L	80.74	0.46%	0.219%	—

1–8 of 79

1 / 10

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

May 2026Transcript AI SummaryPPTREC
Jan 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

30

Final dividend29 May 2026 · ex-date₹9.3
Interim dividend11 Feb 2026 · ex-date₹12.7
Final dividend30 Jul 2025 · ex-date₹7
Interim dividend7 Feb 2025 · ex-date₹8.5
Final dividend14 Aug 2024 · ex-date₹6.75
Interim dividend16 Feb 2024 · ex-date₹5.5
Final dividend17 Aug 2023 · ex-date₹9.25
Interim dividend17 Feb 2023 · ex-date₹8.5
Final dividend12 Aug 2022 · ex-date₹8
Interim dividend23 Feb 2022 · ex-date₹8.5
Final dividend1 Sept 2021 · ex-date₹8
Interim dividend18 Feb 2021 · ex-date₹8.5
Final dividend22 Sept 2020 · ex-date₹1
Interim dividend3 Mar 2020 · ex-date₹10
Dividend dividend14 Aug 2019 · ex-date₹5
Dividend dividend27 Aug 2018 · ex-date₹2
Dividend dividend11 Sept 2017 · ex-date₹1
Final dividend11 Aug 2016 · ex-date₹0.5
Interim dividend17 Mar 2016 · ex-date₹4.5
Special dividend6 Aug 2015 · ex-date₹10
Dividend dividend6 Aug 2015 · ex-date₹4
Dividend dividend4 Sept 2014 · ex-date₹3
Dividend dividend1 Aug 2013 · ex-date₹3
Final dividend19 Jul 2012 · ex-date₹1
Interim dividend29 Aug 2011 · ex-date₹40
Dividend dividend14 Jul 2011 · ex-date₹2
Dividend dividend15 Jul 2010 · ex-date₹2
Dividend dividend2 Jul 2009 · ex-date₹1
Dividend dividend3 Jul 2008 · ex-date₹0.5
Final dividend12 Jul 2007 · ex-date₹1.5

1

Face value ₹2 → ₹118 Sept 2023 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

5 announcementsExport CSV

8 Jul 2026, 11:28 amCompany Update

Intimation Of Effective Date Of Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders

General PDF

Loading announcements…

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	64.5%	65.7%	65.2%	62.9%	66.1%	66.4%	68.7%
EBITDA margin %	21.3%	27.4%	22.4%	22.1%	25.7%	26.3%	26.7%
EBIT margin %	17.5%	24.1%	19.4%	18.5%	21.8%	22%	22.3%
PAT margin %	15.4%	22%	15.9%	13%	15.9%	16.8%	17.1%
Working capital
Receivable days	71	70	84	67	72	76	69
Inventory days	159	181	178	135	155	147	192
Payable days	97	97	97	75	110	114	110
NWC days	133	153	164	127	117	109	151
Leverage
Current ratio	3.43	4.5	3.32	2.8	2.15	3.06	4.98
Debt to EBITDA	0.08	0.06	0.05	0.79	0.4	0.01	0
Debt to equity	0.02	0.02	0.01	0.22	0.12	0	0
Interest coverage	119.4	83.4	99.6	16.4	18	76.7	176.9
Asset turnover	0.97	0.91	0.93	0.89	0.87	0.92	0.83
Return ratios
Return on assets %	15%	20%	14.8%	11.5%	13.8%	15.4%	14.3%
Return on capital employed %	24%	35.5%	24.8%	22.6%	26%	26.6%	24.6%
Return on equity %	19%	24.8%	18.1%	16.5%	18.9%	19.2%	17.1%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
8 Jul 2026, 11:28 am	Company Update General	Intimation Of Effective Date Of Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders	PDF
7 Jul 2026, 9:15 pm	Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	PDF
7 Jul 2026, 8:04 pm	Corp. Action Record Date	Record Date For The Purpose Of Determining The Shareholders Of The Company Who Shall Be Entitled To Receive Fully Paid-Up Equity Shares Of Torrent Pharma As Per The Share Exchange Ratio	PDF
7 Jul 2026, 6:06 pm	Company Update General	Receipt Of Certified Copy Of Order Passed By National Company Law Tribunal, Ahmedabad Bench ('NCLT') Regarding The Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders.	PDF
6 Jul 2026, 6:51 pm	Company Update General	Pronouncement Of Final Order By The Hon'Ble National Company Law Tribunal, Ahmedabad Bench Sanctioning The Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders	PDF

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	167	201	123	194	276	315	170	626	801	902	704
	-48	-45	-21	-28	24	-231	2	-962	-404	-296	-586
	-117	-184	-60	-156	-306	87	-138	357	-385	-580	-123
Net cash flow	2	-28	43	11	-6	172	34	20	11	27	-5
Free cash flow	-18	45	86	145	203	267	107	553	674	805	704
CFO / Operating profit %	—	—	—	—	73%	56.2%	31.3%	89.9%	89.3%	87.5%	63.6%

Jb Chemicals & Pharmaceuticals Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

30

1

Announcements

30

1

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Jb Chemicals & Pharmaceuticals Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Dividends30

Stock splits1

Announcements

Dividends30

Stock splits1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

30

1

30

1